- Home
- MLTX vs DMLP Comparison
MLTX vs DMLP Comparison
Compare MLTX & DMLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MLTX | DMLP |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2020 | 2002 |
Fundamental Metrics
Financial Performance| Metric | MLTX | DMLP |
|---|---|---|
| Price | $18.95 | $27.56 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $27.50 | N/A |
| AVG Volume (30 Days) | ★ 900.0K | 162.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 9.98% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.59 |
| Revenue | N/A | ★ $152,832,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $45.93 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.95 | $20.85 |
| 52 Week High | $62.75 | $28.95 |
Technical Indicators
Market Signals| Indicator | MLTX | DMLP |
|---|---|---|
| Relative Strength Index (RSI) | 58.86 | 51.37 |
| Support Level | $15.54 | $27.41 |
| Resistance Level | $19.16 | $28.81 |
| Average True Range (ATR) | 0.91 | 0.74 |
| MACD | 0.17 | -0.02 |
| Stochastic Oscillator | 84.64 | 43.40 |
Price Performance
Historical ComparisonAbout MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
About DMLP Dorchester Minerals L.P.
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits, and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonuses, and others.